broncho-vaxom adultos n/a capsula
om pharma s.a. - droguerÍa - lisados bacterianos liofilizados - capsula - n/a - por capsula - - otros productos para el sistema respiratorios
equinacea arkopharma cápsulas duras
arkopharma laboratorios s.a. - echinacea purpurea - cÁpsula dura - 250 mg - echinacea purpurea 250 mg - otros productos para el sistema respiratorio
echinasor 250 mg capsulas.
soria natural, s.a. - echinacea angustifolia - excipientes: n/a - otros productos para el sistema respiratorio - otros productos para el sistema respiratorio -
broncho-vaxom niños otros biologicos granulos para solucion oral
om pharma s.a. - droguerÍa - liofilizado estandarizado de lisados bacterianos - granulos para solucion oral - por sobre - - otros productos para el sistema respiratorios
mentholatum®
medifarma s.a.. - alcanfor; mentol; salicilato de metilo - ungüento - 9 g; 1,35 g; 0,333 g
inoxgen 400 ppm mol/mol gas comprimido medicinal
nippon gases espana slu - nitrico oxido - gas comprimido medicinal - 400 ppm mol/mol - nitrico oxido 400 ppm mol/mol - Óxido nítrico
oxido nitrico medicinal praxair 400 ppm mol/mol, gas para inhalacion en botella
praxair espana s.l.u. - nitrico oxido - gas para inhalacion - 400 ppm mol/mol - nitrico oxido 400 ppm mol/mol - Óxido nítrico
palmidrol almirall 500 mg/5 ml suspension oral
almirall, s.a. - palmidrol - excipientes: alcohol etilico (etanol),carmelosa sodica,xantano, goma de,metilparabeno (e 218),propilparabeno (e 216),sacarina sodica - otros productos para el sistema respiratorio - otros productos para el sistema respiratorio - palmidrol
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosis quística - otros productos del sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - fibrosis quística - otros productos del sistema respiratorio - orkambi comprimidos está indicado para el tratamiento de la fibrosis quística (fq) en pacientes mayores de 6 años y más que son homocigotos para la mutación f508del en el gen cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.